urea has been researched along with Cancer of Prostate in 109 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The technique was extended to polarize four 13C labelled substrates potentially providing information on pH, metabolism, necrosis and perfusion, namely [1-(13)C]pyruvic acid, 13C sodium bicarbonate, [1,4-(13)C]fumaric acid, and 13C urea with high levels of solution polarization (17." | 3.76 | Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. ( Bok, R; Chen, AP; Hu, S; Keshari, KR; Kurhanewicz, J; Larson, PE; Macdonald, JM; Nelson, SJ; Van Criekinge, M; Vigneron, DB; Wilson, DM, 2010) |
| "Prostatic acid phosphatase was purified from prostatic adenomas." | 3.66 | Prostatic acid phosphatase, purification and iodination using Iodogen. ( Nustad, K; Skinningsrud, A, 1982) |
| "The purpose of this Functional Imaging Liver Cancer (FLIC) trial is to assess the ability of 18F-DCFPyL-PET/CT to detect sites of HCC." | 3.11 | Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma. ( Choyke, PL; Chung, JY; Escorcia, FE; Hernandez, J; Jakhete, N; Jones, J; Kassin, M; Lindenberg, L; Maass-Moreno, R; Mena, E; Molitoris, JK; Monge, C; Rabiee, A; Saboury, B; Salerno, KE; Shih, J; Turkbey, B; Unger, KR; Wood, B, 2022) |
| "Nine patients with suspected prostate cancer recurrence, eight with CIM evidence of metastatic prostate cancer and one with biochemical recurrence, were imaged with [(18)F]DCFPyL PET/CT." | 2.82 | PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. ( Antonarakis, ES; Blackford, AL; Carducci, M; Chen, Y; Cho, SY; Dannals, RF; Eisenberger, M; Fan, H; Macura, KJ; Mease, RC; Mena, E; Nadal, R; Pomper, MG; Rowe, SP; Szabo, Z, 2016) |
| "The rising incidence rate of prostate cancer (PCa) has promoted the development of new diagnostic and therapeutic radiopharmaceuticals during the last decades." | 2.66 | Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications. ( Ciarmiello, A; Duce, V; Giovacchini, G; Giovannini, E; Pastorino, S; Riondato, M; Uccelli, L, 2020) |
| "With the exception of Renal Cell Carcinoma (RCC), NPCaT demonstrated no or low PSMA expression." | 1.72 | Non-prostate cancer tumours: incidence on ( O'Connor, D; Perry, E; Sharma, S; Sutherland, TR; Talwar, A; Taubman, K; Wong, LM, 2022) |
| "Since prostate cancer is the most commonly diagnosed malignancy in men, the theranostic approach has become very attractive since the discovery of urea-based PSMA inhibitors." | 1.72 | Production and Quality Control of [ ( Boschi, S; Cuni, C; Di Iorio, V; Masini, C; Monti, M; Paganelli, G; Severi, S, 2022) |
| "To target prostate cancer cells, a β-cyclodextrin perfunctionalised with dipeptide-like urea arms, a well-established mimic of a selective ligand against PSMA, is herein reported, to develop a multivalent drug delivery and targeting system." | 1.72 | Functionalization of β-cyclodextrin with a urea-based PSMA ligand and preliminary studies on targeting prostate cancer cells. ( Bortolotto, V; Del Grosso, E; Genazzani, AA; Grolla, AA; Imperio, D; Moro, M; Panza, L, 2022) |
| "Radio-recurrent prostate cancer is typically detected by a rising prostate-specific antigen and may reflect local or distant disease." | 1.56 | A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. ( Archer, S; Bauman, G; Berlin, A; Boylan, C; Chung, HT; Chung, P; Emmett, L; Helou, J; Kapoor, A; Liu, W; Loblaw, A; Lock, M; Metser, U; Morton, G; Pond, GR; Rachinsky, I; Sexton, T; Wolfson, R; Zukotynski, K, 2020) |
| "Although prostate cancer is a leading cause of cancer death, its aetiology is not well understood." | 1.56 | Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank. ( Allen, NE; Andrews, C; Fensom, GK; Key, TJ; Martin, RM; Perez-Cornago, A; Travis, RC; Van Hemelrijck, M; Watts, EL, 2020) |
| "Prostate cancer is one of the most common cancers in the world." | 1.51 | Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer. ( Chun, S; Chung, HJ; Jeong, BH; Kim, HK; Kwon, YD; La, MT; Lee, SH; Lee, SJ; Oh, JM, 2019) |
| "The role of F-DCFPyL (PSMA) PET/CT in prostate cancer is evolving and has been demonstrated to have a higher sensitivity than conventional bone scan and CT scan." | 1.51 | Concomitant Prostate Carcinoma and Follicular Lymphoma: "Flip-Flop" Appearances on PSMA and FDG PET/CT Scans. ( Bosco, A; Dhiantravan, N; Hovey, E; Wegner, EA, 2019) |
| "CDC6 expression is increased during prostate cancer (PCa) progression and positively correlates with AR in PCa tissues." | 1.46 | Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. ( Aparicio, AM; Broom, B; Corn, PG; Gallick, GE; Karanika, S; Karantanos, T; Li, L; Li, S; Maity, SN; Manyam, GC; Navone, N; Park, S; Song, JH; Thompson, TC; Troncoso, P; Wang, J; Yang, G; Zhang, W; Zuo, X, 2017) |
| "Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50)." | 1.42 | Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. ( Antonarakis, ES; Bhatnagar, A; Chen, Y; Cho, SY; Dannals, RF; Eisenberger, MA; Fan, H; Mease, RC; Mena, E; Nidal, R; Plyku, D; Pomper, MG; Rowe, SP; Sgouros, G; Szabo, Z; Vranesic, M, 2015) |
| "Involved lymph node and bone metastases were exposed to estimated absorbed doses upwards of 300 Gy." | 1.40 | Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. ( Afshar-Oromieh, A; Armor, T; Babich, JW; Debus, J; Haberkorn, U; Hadaschik, B; Joyal, J; Kopka, K; Mier, W; Stubbs, JB; Zechmann, CM, 2014) |
| " These results suggest that choice of chelator is an important pharmacokinetic consideration in the development of (99m)Tc-labeled radiopharmaceuticals targeting PSMA." | 1.39 | Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). ( Byun, Y; Falk, A; Foss, CA; Mease, RC; Nimmagadda, S; Pomper, MG; Pullambhatla, M; Ray Banerjee, S, 2013) |
| "Co-treatment of troglitazone with a GSK-3β inhibitor (AR-a014418) or GSK-3β siRNA significantly augmented the inhibitory effect of troglitazone on the NFκB activity and on prostate cancer cell growth inhibition and apoptotic cell death." | 1.37 | Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression. ( Ban, JO; Han, SB; Hong, JT; Kang, KW; Moon, DC; Oh, JH; Son, SM; Song, HS; Song, MJ; Won, D, 2011) |
| "PSMA is upregulated in prostate cancer epithelia and in the neovasculature of most solid tumors." | 1.37 | 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. ( Byun, Y; Chen, Y; Foss, CA; Mease, RC; Nimmagadda, S; Pomper, MG; Pullambhatla, M; Senthamizhchelvan, S; Sgouros, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (8.26) | 18.7374 |
| 1990's | 3 (2.75) | 18.2507 |
| 2000's | 5 (4.59) | 29.6817 |
| 2010's | 52 (47.71) | 24.3611 |
| 2020's | 40 (36.70) | 2.80 |
| Authors | Studies |
|---|---|
| Currie, GM | 1 |
| Trifunovic, M | 1 |
| Liu, J | 2 |
| Kim, S | 1 |
| Gurney, H | 1 |
| Raman, S | 1 |
| Keyes, M | 1 |
| Oh, J | 1 |
| Rousseau, E | 1 |
| Krauze, A | 1 |
| Wilson, D | 1 |
| Bénard, F | 1 |
| Bakht, MK | 1 |
| Hayward, JJ | 1 |
| Shahbazi-Raz, F | 1 |
| Skubal, M | 1 |
| Tamura, R | 1 |
| Stringer, KF | 1 |
| Meister, D | 1 |
| Venkadakrishnan, VB | 1 |
| Xue, H | 1 |
| Pillon, A | 1 |
| Stover, M | 1 |
| Tronchin, A | 1 |
| Fifield, BA | 1 |
| Mader, L | 1 |
| Ku, SY | 1 |
| Cheon, GJ | 2 |
| Kang, KW | 3 |
| Wang, Y | 4 |
| Dong, X | 2 |
| Beltran, H | 1 |
| Grimm, J | 1 |
| Porter, LA | 1 |
| Trant, JF | 1 |
| Wurzer, A | 1 |
| Kunert, JP | 1 |
| Fischer, S | 1 |
| Felber, V | 1 |
| Beck, R | 1 |
| Rose, F | 1 |
| D'Alessandria, C | 1 |
| Weber, W | 1 |
| Wester, HJ | 1 |
| Parathithasan, N | 1 |
| Perry, E | 3 |
| Taubman, K | 3 |
| Hegarty, J | 1 |
| Talwar, A | 3 |
| Wong, LM | 3 |
| Sutherland, T | 1 |
| Rodnick, ME | 1 |
| Sollert, C | 1 |
| Stark, D | 1 |
| Clark, M | 1 |
| Katsifis, A | 1 |
| Hockley, BG | 1 |
| Parr, DC | 1 |
| Frigell, J | 1 |
| Henderson, BD | 1 |
| Bruton, L | 1 |
| Preshlock, S | 1 |
| Abghari-Gerst, M | 1 |
| Piert, MR | 1 |
| Fulham, MJ | 1 |
| Eberl, S | 1 |
| Gagnon, K | 1 |
| Scott, PJH | 1 |
| Sharma, S | 1 |
| O'Connor, D | 1 |
| Sutherland, TR | 2 |
| Liu, Y | 8 |
| Zhang, X | 8 |
| Zhang, J | 7 |
| Xu, B | 3 |
| Zhou, H | 1 |
| Chen, K | 2 |
| Li, Y | 6 |
| Xu, X | 2 |
| Di Iorio, V | 1 |
| Boschi, S | 1 |
| Cuni, C | 1 |
| Monti, M | 1 |
| Severi, S | 1 |
| Paganelli, G | 1 |
| Masini, C | 1 |
| Lu, Y | 2 |
| Li, C | 2 |
| Imperio, D | 1 |
| Grolla, AA | 1 |
| Moro, M | 1 |
| Bortolotto, V | 1 |
| Del Grosso, E | 1 |
| Genazzani, AA | 1 |
| Panza, L | 1 |
| Ulaner, GA | 1 |
| Thomsen, B | 1 |
| Bassett, J | 1 |
| Torrey, R | 1 |
| Cox, C | 1 |
| Lin, K | 1 |
| Patel, T | 1 |
| Techasith, T | 1 |
| Mauguen, A | 1 |
| Rowe, SP | 12 |
| Lindenberg, L | 2 |
| Mena, E | 4 |
| Choyke, P | 1 |
| Yoshida, J | 1 |
| Cilibrizzi, A | 1 |
| Wang, JT | 1 |
| Memdouh, S | 1 |
| Iacovone, A | 1 |
| McElroy, K | 1 |
| Jaffar, N | 1 |
| Young, JD | 1 |
| Hider, RC | 1 |
| Blower, P | 1 |
| Al-Jamal, K | 1 |
| Abbate, V | 1 |
| Shih, J | 1 |
| Chung, JY | 1 |
| Jones, J | 1 |
| Rabiee, A | 1 |
| Monge, C | 1 |
| Turkbey, B | 1 |
| Salerno, KE | 1 |
| Kassin, M | 1 |
| Wood, B | 1 |
| Hernandez, J | 1 |
| Maass-Moreno, R | 1 |
| Saboury, B | 1 |
| Jakhete, N | 1 |
| Molitoris, JK | 1 |
| Unger, KR | 1 |
| Choyke, PL | 2 |
| Escorcia, FE | 1 |
| Spinali, KL | 1 |
| Papke, DJ | 1 |
| Shah, HJ | 1 |
| Wang, X | 6 |
| Chen, Y | 10 |
| Xiong, Y | 1 |
| Zhang, L | 4 |
| Wang, B | 1 |
| Cui, M | 3 |
| Werner, RA | 1 |
| Lütje, S | 1 |
| Habacha, B | 1 |
| Bundschuh, L | 1 |
| Higuchi, T | 1 |
| Buck, AK | 1 |
| Kosmala, A | 1 |
| Lapa, C | 1 |
| Essler, M | 1 |
| Lodge, MA | 1 |
| Pienta, KJ | 7 |
| Eisenberger, MA | 2 |
| Markowski, MC | 1 |
| Gorin, MA | 8 |
| Pomper, MG | 18 |
| Bundschuh, RA | 1 |
| Sui, Y | 1 |
| Duan, X | 2 |
| Chu, Y | 2 |
| Yang, X | 7 |
| Hasnowo, LA | 1 |
| Larkina, MS | 1 |
| Plotnikov, E | 1 |
| Bodenko, V | 1 |
| Yuldasheva, F | 1 |
| Stasyuk, E | 1 |
| Petrov, SA | 1 |
| Zyk, NY | 1 |
| Machulkin, AE | 1 |
| Vorozhtsov, NI | 1 |
| Beloglazkina, EK | 1 |
| Nenajdenko, VG | 1 |
| Tolmachev, V | 1 |
| Orlova, A | 1 |
| Majouga, AG | 1 |
| Yusubov, MS | 1 |
| Sengupta, S | 1 |
| Krishnan, MA | 1 |
| Pandit, A | 1 |
| Dudhe, P | 1 |
| Sharma, R | 1 |
| Chelvam, V | 1 |
| Zia, NA | 1 |
| Cullinane, C | 1 |
| Van Zuylekom, JK | 1 |
| Waldeck, K | 1 |
| McInnes, LE | 1 |
| Buncic, G | 1 |
| Haskali, MB | 1 |
| Roselt, PD | 1 |
| Hicks, RJ | 1 |
| Donnelly, PS | 1 |
| Liu, W | 1 |
| Zukotynski, K | 1 |
| Emmett, L | 1 |
| Chung, HT | 1 |
| Chung, P | 1 |
| Wolfson, R | 1 |
| Rachinsky, I | 1 |
| Kapoor, A | 1 |
| Metser, U | 1 |
| Loblaw, A | 1 |
| Morton, G | 1 |
| Sexton, T | 1 |
| Lock, M | 1 |
| Helou, J | 1 |
| Berlin, A | 1 |
| Boylan, C | 1 |
| Archer, S | 1 |
| Pond, GR | 1 |
| Bauman, G | 1 |
| Liu, F | 1 |
| Kwon, H | 1 |
| Byun, Y | 4 |
| Minn, I | 3 |
| Cai, X | 2 |
| Yang, Z | 4 |
| Xi, Z | 2 |
| Qin, H | 1 |
| Zhang, V | 1 |
| Bok, RA | 3 |
| Santos, RD | 1 |
| Cunha, JA | 1 |
| Hsu, IC | 1 |
| Santos Bs, JD | 1 |
| Lee, JE | 1 |
| Sukumar, S | 2 |
| Larson, PEZ | 1 |
| Vigneron, DB | 4 |
| Wilson, DM | 2 |
| Sriram, R | 1 |
| Kurhanewicz, J | 3 |
| Farahani, H | 1 |
| Alaee, M | 1 |
| Amri, J | 1 |
| Baghinia, MR | 1 |
| Rafiee, M | 1 |
| Zukotynski, KA | 1 |
| Jadvar, H | 1 |
| Potvin, K | 1 |
| Cho, SY | 4 |
| Kim, CK | 1 |
| Winquist, E | 1 |
| Koene, BPF | 1 |
| Bodar, YJL | 2 |
| Meijer, D | 3 |
| Jaspars, EH | 1 |
| Vis, AN | 3 |
| Oprea-Lager, DE | 3 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 10 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 2 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Zhou, L | 2 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Wang, J | 6 |
| Zhang, E | 1 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Li, J | 8 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, W | 1 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 1 |
| Zhu, J | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Zhang, Y | 4 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 3 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 2 |
| Zhang, M | 4 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 2 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Xi, J | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 1 |
| He, Z | 2 |
| Chen, B | 1 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 2 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Perez-Cornago, A | 1 |
| Fensom, GK | 1 |
| Andrews, C | 1 |
| Watts, EL | 1 |
| Allen, NE | 1 |
| Martin, RM | 1 |
| Van Hemelrijck, M | 1 |
| Key, TJ | 1 |
| Travis, RC | 1 |
| Jansen, BHE | 2 |
| Wondergem, M | 7 |
| Srbljin, S | 3 |
| Vellekoop, AE | 1 |
| Keizer, B | 1 |
| van der Zant, FM | 7 |
| Hoekstra, OS | 2 |
| Nieuwenhuijzen, JA | 1 |
| Dahele, M | 1 |
| Ng, M | 1 |
| Booth, R | 1 |
| Saniee, F | 1 |
| Shabani Ravari, N | 1 |
| Goodarzi, N | 1 |
| Amini, M | 1 |
| Atyabi, F | 1 |
| Saeedian Moghadam, E | 1 |
| Dinarvand, R | 1 |
| Zeng, Q | 1 |
| Xie, T | 1 |
| Yao, S | 1 |
| Qu, Z | 1 |
| Jia, X | 1 |
| Lin, Y | 1 |
| He, Q | 1 |
| Luo, Y | 1 |
| Roy, J | 2 |
| White, ME | 1 |
| Basuli, F | 1 |
| Opina, ACL | 1 |
| Wong, K | 1 |
| Riba, M | 1 |
| Ton, AT | 1 |
| Jansson, KH | 1 |
| Edmondson, E | 1 |
| Butcher, D | 1 |
| Lin, FI | 1 |
| Kelly, K | 1 |
| Jagoda, EM | 1 |
| Yang, C | 1 |
| Ma, D | 1 |
| Lu, L | 1 |
| Rogers, OC | 1 |
| Rosen, DM | 1 |
| Antony, L | 1 |
| Harper, HM | 1 |
| Das, D | 1 |
| Mease, RC | 8 |
| Denmeade, SR | 1 |
| Marashdeh, W | 1 |
| Ross, AE | 4 |
| Allaf, ME | 1 |
| Chu, LC | 1 |
| Macura, KJ | 2 |
| Peper, JGK | 1 |
| Knol, RJJ | 6 |
| Matsuoka, D | 2 |
| Watanabe, H | 2 |
| Shimizu, Y | 1 |
| Kimura, H | 3 |
| Ono, M | 3 |
| Saji, H | 3 |
| Cornelis, FH | 1 |
| Durack, JC | 1 |
| Morris, MJ | 1 |
| Scher, HI | 1 |
| Solomon, SB | 1 |
| Özgeriş, B | 1 |
| Akbaba, Y | 1 |
| Özdemir, Ö | 1 |
| Türkez, H | 1 |
| Göksu, S | 1 |
| Broos, WAM | 3 |
| Kocken, M | 1 |
| Vlottes, PW | 1 |
| Lv, Q | 1 |
| Yang, J | 1 |
| Zhang, R | 1 |
| Kwon, YD | 1 |
| Oh, JM | 1 |
| La, MT | 1 |
| Chung, HJ | 1 |
| Lee, SJ | 1 |
| Chun, S | 1 |
| Lee, SH | 1 |
| Jeong, BH | 1 |
| Kim, HK | 1 |
| Chaussé, G | 1 |
| Laufer, J | 1 |
| Abikhzer, G | 1 |
| Probst, S | 1 |
| Gomez, E | 1 |
| Tran, PT | 1 |
| Rafimanesh-Sadr, L | 1 |
| Yaqub, M | 1 |
| Voortman, J | 1 |
| Cysouw, MCF | 1 |
| Windhorst, AD | 1 |
| Schuit, RC | 1 |
| Kramer, GM | 1 |
| van den Eertwegh, AJM | 1 |
| Schwarte, LA | 1 |
| Hendrikse, NH | 1 |
| van Moorselaar, RJA | 1 |
| Boellaard, R | 1 |
| Endepols, H | 1 |
| Morgenroth, A | 1 |
| Zlatopolskiy, BD | 2 |
| Krapf, P | 2 |
| Zischler, J | 1 |
| Richarz, R | 2 |
| Muñoz Vásquez, S | 1 |
| Neumaier, B | 2 |
| Mottaghy, FM | 1 |
| Dhiantravan, N | 1 |
| Hovey, E | 1 |
| Bosco, A | 1 |
| Wegner, EA | 1 |
| Pastorino, S | 1 |
| Riondato, M | 1 |
| Uccelli, L | 1 |
| Giovacchini, G | 1 |
| Giovannini, E | 1 |
| Duce, V | 1 |
| Ciarmiello, A | 1 |
| Hillier, SM | 3 |
| Maresca, KP | 4 |
| Lu, G | 1 |
| Merkin, RD | 1 |
| Marquis, JC | 3 |
| Zimmerman, CN | 2 |
| Eckelman, WC | 4 |
| Joyal, JL | 4 |
| Babich, JW | 5 |
| Ray Banerjee, S | 1 |
| Pullambhatla, M | 4 |
| Foss, CA | 5 |
| Falk, A | 1 |
| Nimmagadda, S | 3 |
| Xing, Y | 1 |
| Reed, GD | 2 |
| Pauly, JM | 1 |
| Kerr, AB | 1 |
| Larson, PE | 4 |
| Harada, N | 2 |
| Peng, ZH | 1 |
| Sima, M | 1 |
| Salama, ME | 1 |
| Kopečková, P | 1 |
| Kopeček, J | 1 |
| Huang, B | 1 |
| Otis, J | 1 |
| Joice, M | 1 |
| Kotlyar, A | 1 |
| Thomas, TP | 1 |
| Bandari, RP | 1 |
| Jiang, Z | 1 |
| Reynolds, TS | 1 |
| Bernskoetter, NE | 1 |
| Szczodroski, AF | 1 |
| Bassuner, KJ | 1 |
| Kirkpatrick, DL | 1 |
| Rold, TL | 1 |
| Sieckman, GL | 1 |
| Hoffman, TJ | 1 |
| Connors, JP | 1 |
| Smith, CJ | 1 |
| Zechmann, CM | 1 |
| Afshar-Oromieh, A | 1 |
| Armor, T | 2 |
| Stubbs, JB | 2 |
| Mier, W | 2 |
| Hadaschik, B | 1 |
| Joyal, J | 1 |
| Kopka, K | 1 |
| Debus, J | 1 |
| Haberkorn, U | 2 |
| Li, L | 2 |
| Chang, W | 1 |
| Yang, G | 2 |
| Ren, C | 1 |
| Karantanos, T | 2 |
| Karanika, S | 2 |
| Yin, J | 1 |
| Shah, PK | 1 |
| Takahiro, H | 1 |
| Dobashi, M | 1 |
| Zhang, W | 2 |
| Efstathiou, E | 1 |
| Maity, SN | 2 |
| Aparicio, AM | 2 |
| Li Ning Tapia, EM | 1 |
| Troncoso, P | 2 |
| Broom, B | 2 |
| Xiao, L | 1 |
| Lee, HS | 1 |
| Lee, JS | 1 |
| Corn, PG | 2 |
| Navone, N | 2 |
| Thompson, TC | 2 |
| Nguyen, TX | 1 |
| Kanduluru, AK | 1 |
| Venkatesh, C | 2 |
| Lv, W | 1 |
| Reddy, PV | 1 |
| Low, PS | 2 |
| Cushman, M | 1 |
| Szabo, Z | 4 |
| Plyku, D | 1 |
| Nidal, R | 1 |
| Antonarakis, ES | 2 |
| Fan, H | 2 |
| Dannals, RF | 2 |
| Vranesic, M | 1 |
| Bhatnagar, A | 1 |
| Sgouros, G | 3 |
| Dietlein, M | 1 |
| Kobe, C | 1 |
| Kuhnert, G | 1 |
| Stockter, S | 1 |
| Fischer, T | 1 |
| Schomäcker, K | 1 |
| Schmidt, M | 1 |
| Dietlein, F | 1 |
| Neubauer, S | 1 |
| Drzezga, A | 2 |
| Kiess, AP | 2 |
| Hobbs, R | 1 |
| Shen, CJ | 1 |
| Banerjee, SR | 2 |
| Rao, A | 1 |
| Mana-Ay, M | 1 |
| Javadi, MS | 1 |
| Leal, JP | 1 |
| Sampei, S | 1 |
| Arimitsu, K | 1 |
| Blackford, AL | 1 |
| Nadal, R | 1 |
| Eisenberger, M | 1 |
| Carducci, M | 1 |
| De Petrocellis, L | 1 |
| Arroyo, FJ | 1 |
| Orlando, P | 1 |
| Schiano Moriello, A | 1 |
| Vitale, RM | 1 |
| Amodeo, P | 1 |
| Sánchez, A | 1 |
| Roncero, C | 1 |
| Bianchini, G | 1 |
| Martín, MA | 1 |
| López-Alvarado, P | 1 |
| Menéndez, JC | 1 |
| Eldehna, WM | 1 |
| Fares, M | 1 |
| Ibrahim, HS | 1 |
| Alsherbiny, MA | 1 |
| Aly, MH | 1 |
| Ghabbour, HA | 1 |
| Abdel-Aziz, HA | 1 |
| Tosoian, JJ | 1 |
| Andreas, D | 1 |
| Lotan, TL | 1 |
| Zuo, X | 1 |
| Song, JH | 1 |
| Manyam, GC | 1 |
| Gallick, GE | 1 |
| Salas Fragomeni, RA | 1 |
| Mijatovic, T | 1 |
| Mahieu, T | 1 |
| Bruyère, C | 1 |
| De Nève, N | 1 |
| Dewelle, J | 1 |
| Simon, G | 1 |
| Dehoux, MJ | 1 |
| van der Aar, E | 1 |
| Haibe-Kains, B | 1 |
| Bontempi, G | 1 |
| Decaestecker, C | 1 |
| Van Quaquebeke, E | 1 |
| Darro, F | 1 |
| Kiss, R | 1 |
| WILBRANDT, W | 1 |
| DE LA CAUDRA, JL | 1 |
| Femia, FJ | 1 |
| Nguyen, N | 1 |
| Barrett, JA | 2 |
| Dhara, S | 1 |
| Garofalo, A | 1 |
| Goossens, L | 1 |
| Lemoine, A | 1 |
| Farce, A | 1 |
| Arlot, Y | 1 |
| Depreux, P | 1 |
| Keshari, KR | 1 |
| Chen, AP | 1 |
| Hu, S | 2 |
| Van Criekinge, M | 1 |
| Bok, R | 1 |
| Nelson, SJ | 1 |
| Macdonald, JM | 1 |
| Kularatne, SA | 1 |
| Santhapuram, HK | 1 |
| Wang, K | 1 |
| Vaitilingam, B | 1 |
| Henne, WA | 1 |
| Ban, JO | 1 |
| Oh, JH | 1 |
| Son, SM | 1 |
| Won, D | 1 |
| Song, HS | 1 |
| Han, SB | 1 |
| Moon, DC | 1 |
| Song, MJ | 1 |
| Hong, JT | 1 |
| Kern, AM | 1 |
| Senthamizhchelvan, S | 1 |
| von Morze, C | 2 |
| Yoshihara, HA | 1 |
| Goga, A | 1 |
| Ardenkjaer-Larsen, JH | 1 |
| Eder, M | 1 |
| Schäfer, M | 1 |
| Bauder-Wüst, U | 1 |
| Hull, WE | 1 |
| Wängler, C | 1 |
| Eisenhut, M | 1 |
| Coleman, RE | 1 |
| Goldsmith, SJ | 1 |
| Vallabhajosula, S | 1 |
| Petry, NA | 1 |
| Cho, S | 1 |
| Stabin, MG | 1 |
| Lim, S | 1 |
| Ryu, JH | 1 |
| Im, C | 1 |
| Yim, CB | 1 |
| MARSHALL, S | 1 |
| Broom, BM | 1 |
| McDonnell, TJ | 1 |
| Subramanian, D | 1 |
| Herzog, A | 1 |
| Skinningsrud, A | 1 |
| Nustad, K | 1 |
| Shi, SR | 1 |
| Chaiwun, B | 1 |
| Young, L | 1 |
| Cote, RJ | 1 |
| Taylor, CR | 1 |
| Quemener, V | 1 |
| Bansard, JY | 1 |
| Delamaire, M | 1 |
| Roth, S | 1 |
| Havouis, R | 1 |
| Desury, D | 1 |
| Moulinoux, JP | 1 |
| Willden, EG | 1 |
| Robinson, MR | 1 |
| Darlington, LG | 1 |
| Ainsworth, JG | 1 |
| Blight, A | 1 |
| Khong, MD | 1 |
| Mann, TA | 1 |
| Waldon, RD | 1 |
| Warburton, EA | 1 |
| Vaughan, ED | 1 |
| Gillenwater, JY | 1 |
| Aubrey, DA | 1 |
| Peeling, WB | 1 |
| Lechner, K | 1 |
| Regele, H | 1 |
| Waldhäusl, W | 1 |
| Karobath, H | 1 |
| Ham, JM | 1 |
| Jones, M | 1 |
| Kemp, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (PyL) in Patients With High Risk and Biochemically Recurrent Prostate Cancer[NCT04700332] | Phase 2 | 184 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| 18F-DCFPyL PET/CT in Hepatocellular Carcinoma[NCT05009979] | Phase 2 | 50 participants (Anticipated) | Interventional | 2023-01-18 | Recruiting | ||
| A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer[NCT05936658] | Phase 3 | 89 participants (Anticipated) | Interventional | 2023-05-08 | Recruiting | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)[NCT02615067] | Phase 3 | 531 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology[NCT01667536] | Phase 2 | 105 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen [NCT03939689] | Phase 2 | 120 participants (Anticipated) | Interventional | 2019-05-30 | Active, not recruiting | ||
| Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand[NCT04266392] | Early Phase 1 | 20 participants (Actual) | Interventional | 2019-12-16 | Completed | ||
| Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers[NCT03585114] | Phase 2 | 11 participants (Actual) | Interventional | 2018-12-11 | Active, not recruiting | ||
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer[NCT03181867] | Phase 2 | 330 participants (Anticipated) | Interventional | 2017-08-03 | Enrolling by invitation | ||
| A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups[NCT05004285] | Phase 3 | 398 participants (Anticipated) | Interventional | 2021-04-28 | Recruiting | ||
| Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer[NCT03173924] | Phase 2 | 180 participants (Anticipated) | Interventional | 2017-06-06 | Enrolling by invitation | ||
| A Phase 1 Pilot Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection (PLND)[NCT01572701] | Phase 1 | 8 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Phase 1 Pilot Comparison Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging to Histology in Men With Prostate Cancer[NCT01615406] | Phase 1 | 9 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Imaging for Prostate Cancer Metastasis Detection - Traditional Imaging (Bone Scan and CT) Versus PSMA-PET-CT, SPECT-CT and Whole-Body MRI[NCT03537391] | 80 participants (Actual) | Interventional | 2018-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For the prostate gland, sensitivity values refer to the number of subjects in the study, i.e., the percentages of true positive subjects correctly identified by the imaging technique. Pathology results were used as the truth standard for all imaging analyses. (NCT01667536)
Timeframe: Within 3-6 hours of dosing SPECT/CT images will be taken
| Intervention | % sensitivity (Number) |
|---|---|
| Drug: 99mTc-MIP-1404 | 94.2 |
For lymph nodes, sensitivity values refer to the number of subjects in the study, i.e., the percentages of true positive subjects correctly identified by the imaging technique. Pathology results were used as the truth standard for all imaging analyses. (NCT01667536)
Timeframe: Within 3-6 hours of dosing SPECT/CT images will be taken
| Intervention | % sensitivity (Number) |
|---|---|
| Drug: 99mTc-MIP-1404 | 33.3 |
"For specific segments of the prostate, a sensitivity value refers to the number of evaluable segments (histologically examined tissue-segments) from all subjects, i.e., the percentages of true positive segments correctly identified by the imaging technique." (NCT01667536)
Timeframe: Within 3-6 hours of dosing SPECT/CT images will be taken
| Intervention | % sensitivity (Number) |
|---|---|
| Drug: 99mTc-MIP-1404 | 44.4 |
"For specific segments of the lymph nodes, a sensitivity value refers to the number of evaluable segments (histologically examined tissue-segments) from all subjects, i.e., the percentages of true positive segments correctly identified by the imaging technique." (NCT01667536)
Timeframe: Within 3-6 hours of dosing SPECT/CT images will be taken
| Intervention | % sensitivity (Number) |
|---|---|
| Drug: 99mTc-MIP-1404 | 8.1 |
Comparative performance characteristics between MIP-1404 imaging and MRI were analyzed for the lymph nodes. MIP-1404 and MRI sensitivities were derived from case positive histopathology results. (NCT01667536)
Timeframe: Within 3-6 hours of dosing SPECT/CT images will be taken
| Intervention | % sensitivity (Number) |
|---|---|
| Drug: 99mTc-MIP-1404 | 33.3 |
| Drug: 99mTc-MIP-1404 + MRI | 12.5 |
Comparative performance characteristics between MIP-1404 imaging and MRI were analyzed for the prostate gland. MIP-1404 and MRI sensitivities were derived from case positive histopathology results. (NCT01667536)
Timeframe: Within 3-6 hours of dosing SPECT/CT images will be taken
| Intervention | % specificity (Number) |
|---|---|
| Drug: 99mTc-MIP-1404 | 93.8 |
| Drug: 99mTc-MIP-1404 + MRI | 85.4 |
5 reviews available for urea and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis of
Topics: Cyclotrons; Edetic Acid; Gallium Radioisotopes; Humans; Male; Positron-Emission Tomography; Prostati | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications.
Topics: Amides; Antibodies, Monoclonal; Aptamers, Nucleotide; Drug Development; Drug Discovery; Glutamates; | 2020 |
Prostate-specific membrane antigen as a target for cancer imaging and therapy.
Topics: Animals; Antigens, Surface; Crystallography, X-Ray; Drug Design; Glutamate Carboxypeptidase II; Huma | 2015 |
Clinical Experience with
Topics: Antigens, Surface; Cysteine; Drug Evaluation, Preclinical; Fluorine Radioisotopes; Glutamate Carboxy | 2017 |
9 trials available for urea and Cancer of Prostate
| Article | Year |
|---|---|
Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigen-Positron Emission Tomography and Computed Tomography Imaging.
Topics: Brachytherapy; Humans; Lysine; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Comput | 2022 |
Topics: Aged; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospecti | 2022 |
Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Fluorodeoxyglucose F18; Humans; Liver | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Contrast Media; Fluorine Radioisotopes; Glutamate Carb | 2021 |
Effects of Fasting on
Topics: Aged; Aged, 80 and over; Biological Transport; Fasting; Humans; Lysine; Male; Middle Aged; Neoplasm | 2018 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Demography; Humans; Lysine; Male; Middle Aged; Positron Emission Tomography | 2016 |
First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.
Topics: Aged; Aged, 80 and over; Cross-Over Studies; Glutamates; Humans; Iodine Radioisotopes; Male; Middle | 2013 |
Plasma zinc legels in prostatic disease.
Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Clinical Trials as Topic; Creatinine; Female; H | 1975 |
96 other studies available for urea and Cancer of Prostate
| Article | Year |
|---|---|
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Ligands; Lysine; Male; Positron Emission Tomography | 2022 |
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
Topics: Animals; Antigens, Surface; Binding Sites; Cell Cycle Proteins; Disease Models, Animal; Disease Prog | 2022 |
Synthesis and Preclinical Evaluation of
Topics: Animals; Gallium; Humans; Ligands; Male; Mice; Prostatic Neoplasms; Serum Albumin, Human; Tissue Dis | 2022 |
Combination of MRI prostate and 18F-DCFPyl PSMA PET/CT detects all clinically significant prostate cancers in treatment-naive patients: An international multicentre retrospective study.
Topics: Humans; Lysine; Magnetic Resonance Imaging; Male; Positron Emission Tomography Computed Tomography; | 2022 |
Non-prostate cancer tumours: incidence on
Topics: Carcinoma, Renal Cell; Humans; Incidence; Kidney Neoplasms; Lysine; Male; Positron Emission Tomograp | 2022 |
Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.
Topics: Humans; Male; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostatic Neopl | 2022 |
A Preliminary Study of PSMA Fluorescent Probe for Targeted Fluorescence Imaging of Prostate Cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorescent Dyes; Humans; Ligands; Male; Mice; Optical | 2022 |
Production and Quality Control of [
Topics: Antigens, Surface; Ascorbic Acid; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, | 2022 |
Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients With Prostate Cancer on 18 F-Prostate-Specific Membrane Antigen PET/CT.
Topics: Aged; Gallium Radioisotopes; Humans; Incidental Findings; Lysine; Male; Pancreatic Neoplasms; Positr | 2022 |
Functionalization of β-cyclodextrin with a urea-based PSMA ligand and preliminary studies on targeting prostate cancer cells.
Topics: Antigens, Surface; beta-Cyclodextrins; Cell Line, Tumor; Doxorubicin; Glutamate Carboxypeptidase II; | 2022 |
PSMA-targeted NIR probes for image-guided detection of prostate cancer.
Topics: Animals; Cell Line, Tumor; Fluorescent Dyes; Humans; Male; Mice; Optical Imaging; Prostatic Neoplasm | 2022 |
Hepatic Small Vessel Neoplasm Mimics Prostate Cancer on 18 F-DCFPyl PET/CT.
Topics: Humans; Lysine; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radioph | 2023 |
Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Glutamate Carboxypeptidase II; Humans; Male; Mice; Pro | 2023 |
Test-retest repeatability of organ uptake on PSMA-targeted
Topics: Humans; Lysine; Male; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostat | 2023 |
Synthesis and characterization of a novel
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Gallium Radioisotopes; Glutamate Carboxypeptidase II; | 2023 |
Synthesis,
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Glutamate Carboxypeptidase II; Humans; Iodine Radioiso | 2023 |
Tyrosine-based asymmetric urea ligand for prostate carcinoma: Tuning biological efficacy through in silico studies.
Topics: Antigens, Surface; Computer Simulation; Glutamate Carboxypeptidase II; Humans; Ligands; Male; Micros | 2019 |
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.
Topics: Animals; Antigens, Surface; Binding Sites; Cell Line, Tumor; Copper Radioisotopes; Dipeptides; Gluta | 2019 |
A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; H | 2020 |
Primary Peripheral Primitive Neuroectodermal Tumor of the Prostate on 18F-DCFPyL PET/CT.
Topics: Adult; Dysuria; Humans; Lysine; Magnetic Resonance Imaging; Male; Neuroectodermal Tumors, Primitive, | 2020 |
(
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorescent Dyes; Glutamate Carboxypeptidase II; Human | 2020 |
Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized
Topics: Animals; Carbon Isotopes; Disease Models, Animal; Dose-Response Relationship, Radiation; Magnetic Re | 2020 |
Serum and Saliva Concentrations of Biochemical Parameters in Men with Prostate Cancer and Benign Prostate Hyperplasia.
Topics: beta 2-Microglobulin; Biomarkers; Case-Control Studies; Creatine Kinase, BB Form; Creatinine; Down-R | 2020 |
Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT.
Topics: Disease Progression; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lysine; Male; Middle Aged; Posi | 2020 |
Cylindroma, an uncommon presentation on
Topics: Carcinoma, Adenoid Cystic; Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic | 2021 |
Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank.
Topics: Adult; Aged; Aspartate Aminotransferases; Biomarkers, Tumor; Blood Glucose; Blood Proteins; Cardiova | 2020 |
Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
Topics: Aged; Humans; Image Processing, Computer-Assisted; Lysine; Male; Middle Aged; Positron Emission Tomo | 2020 |
[
Topics: Fluorine Radioisotopes; Humans; Lysine; Male; Neoplasm Recurrence, Local; Positron Emission Tomograp | 2021 |
Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Topics: Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Carri | 2021 |
Causal Associations between Serum Urea and Cancer: A Mendelian Randomization Study.
Topics: Breast Neoplasms; Carcinoma, Renal Cell; Female; Genome-Wide Association Study; Humans; Kidney Neopl | 2021 |
Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Disease Models, An | 2021 |
Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing.
Topics: Antigens, Surface; Gene Silencing; Glutamate Carboxypeptidase II; Glutamic Acid; Humans; Lysine; Mal | 2021 |
Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors.
Topics: Carboxypeptidases; Cell Line, Tumor; Drug Delivery Systems; Humans; Immunotoxins; Kallikreins; Male; | 2021 |
FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
Topics: Gallium Isotopes; Gallium Radioisotopes; Humans; Lysine; Male; Positron-Emission Tomography; Prostat | 2021 |
Prostate Cancer Local Recurrence Detected With Both
Topics: Aged; Antigens, Surface; Carboxylic Acids; Cyclobutanes; Fluorine Radioisotopes; Glutamate Carboxype | 2017 |
Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Biomarkers, Tumor; Computer Simulation; Diagnosis, Diffe | 2017 |
An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT.
Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lysine; Magnetic Resonance Imaging; Male; | 2017 |
High 18Fluor-DCFPyL Uptake in Adrenal Adenomas.
Topics: Adenoma; Adrenal Gland Neoplasms; Aged; Biological Transport; Humans; Lysine; Male; Positron Emissio | 2017 |
Synthesis and evaluation of a novel near-infrared fluorescent probe based on succinimidyl-Cys-C(O)-Glu that targets prostate-specific membrane antigen for optical imaging.
Topics: Animals; Cell Line, Tumor; Fluorescent Dyes; Humans; Iodine Radioisotopes; Male; Maleimides; Mice; P | 2017 |
Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Topics: Aged; Antigens, Surface; Carbon Radioisotopes; Choline; Cryosurgery; Glutamate Carboxypeptidase II; | 2017 |
Synthesis and Anticancer Activity of Novel Ureas and Sulfamides Incorporating 1-Aminotetralins.
Topics: Analysis of Variance; Antineoplastic Agents; Cell Death; Cell Line; Cell Line, Tumor; Cell Survival; | 2017 |
Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Topics: Adenocarcinoma; Aged; Humans; Lysine; Male; Neoplasm Metastasis; Neurosecretory Systems; Positron Em | 2018 |
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Glutamate Carb | 2018 |
Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer.
Topics: Animals; Antigens, Surface; Cell Hypoxia; Cell Line, Tumor; Female; Fluorescent Dyes; Glutamate Carb | 2019 |
Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT.
Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Hemangioma; Humans; Lysine; Magnetic Resonan | 2019 |
Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.
Topics: Aged; Antigens, Surface; Bone Marrow; Glutamate Carboxypeptidase II; Humans; Lysine; Male; Positron | 2019 |
Effect of forced diuresis during 18F-DCFPyL PET/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder.
Topics: Aged; Aged, 80 and over; Artifacts; Cohort Studies; Diuresis; Female; Furosemide; Humans; Kidney; Ly | 2019 |
Simplified Methods for Quantification of
Topics: Aged; Aged, 80 and over; Biological Transport; Humans; Lysine; Male; Middle Aged; Positron-Emission | 2019 |
Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
Topics: Animals; Antigens, Surface; Autoradiography; Gallium Isotopes; Gallium Radioisotopes; Ganglia; Gangl | 2019 |
18F-DCFPyL PET/CT in a Single Large Metastasis With Prostate-Specific Antigen Level of 856 ng/mL.
Topics: Aged; Glutamate Carboxypeptidase II; Humans; Lysine; Male; Neoplasm Metastasis; Positron Emission To | 2019 |
Concomitant Prostate Carcinoma and Follicular Lymphoma: "Flip-Flop" Appearances on PSMA and FDG PET/CT Scans.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular; Lysine; Male; Neoplasm Metastasis; Neopl | 2019 |
18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer.
Topics: Aged; Biological Transport; Humans; Incidental Findings; Lymphoma, Follicular; Lysine; Male; Positro | 2020 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Topics: Acetates; Animals; Antigens, Surface; Biological Transport; Cell Line, Tumor; Chelating Agents; Glut | 2013 |
Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
Topics: Animals; Antigens, Surface; Chelating Agents; Glutamate Carboxypeptidase II; Hydrazines; Hydrophobic | 2013 |
Optimal variable flip angle schemes for dynamic acquisition of exchanging hyperpolarized substrates.
Topics: Adenocarcinoma; Algorithms; Animals; Biotransformation; Carbon Isotopes; Computer Simulation; Image | 2013 |
Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.
Topics: Animals; Antigens, Surface; Binding, Competitive; Cell Line, Tumor; Glutamate Carboxypeptidase II; H | 2013 |
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Topics: Acrylamides; Adenocarcinoma; Animals; Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; De | 2013 |
PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Topics: Antigens, Surface; Click Chemistry; Dendrimers; Drug Delivery Systems; Glutamate Carboxypeptidase II | 2014 |
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Topics: Acetates; Amino Acids, Neutral; Aminocaproic Acid; Animals; Antigens, Surface; Biological Transport; | 2014 |
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Glutamates; Humans; Iodine Radioisotopes; Ma | 2014 |
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Topics: Animals; BRCA1 Protein; Carrier Proteins; Castration; Cell Cycle Checkpoints; DNA Damage; DNA-Bindin | 2014 |
DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Drug Design; Glutarates; Humans; In | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Feasibility Studies; Glutamate Carboxypeptidase II; Humans; Lysine; Male; M | 2015 |
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Topics: Aged; Aged, 80 and over; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Liver; Lysine | 2015 |
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Topics: Aged; Aged, 80 and over; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Liver; Lysine | 2015 |
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Topics: Aged; Aged, 80 and over; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Liver; Lysine | 2015 |
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Topics: Aged; Aged, 80 and over; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Liver; Lysine | 2015 |
Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Humans; Iodine Radioisotopes; Kallikreins; Lysine; Male; | 2015 |
PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?
Topics: Antigens, Surface; Bone Neoplasms; Glutamate Carboxypeptidase II; Humans; Lysine; Male; Middle Aged; | 2016 |
Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
Topics: Animals; Antigens, Surface; Drug Design; Glutamate Carboxypeptidase II; Male; Mice; Organotechnetium | 2016 |
Tetrahydroisoquinoline-Derived Urea and 2,5-Diketopiperazine Derivatives as Selective Antagonists of the Transient Receptor Potential Melastatin 8 (TRPM8) Channel Receptor and Antiprostate Cancer Agents.
Topics: Animals; Antineoplastic Agents; Calcium; Cell Proliferation; Diketopiperazines; Dose-Response Relati | 2016 |
Synthesis and Cytotoxic Activity of Biphenylurea Derivatives Containing Indolin-2-one Moieties.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Screening Assays, Ant | 2016 |
Correlation of PSMA-Targeted
Topics: Aged; Antigens, Surface; Carcinoma, Neuroendocrine; Glutamate Carboxypeptidase II; Humans; Lysine; M | 2017 |
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Topics: Androgen Receptor Antagonists; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Biomarker | 2017 |
UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence | 2008 |
Mechanical pressure boosting and pressure transfer with low volume displacement.
Topics: Biochemical Phenomena; Cysteine; Cystine; Humans; Male; Methionine; Pressure; Prostatic Neoplasms; U | 1947 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Evaluation, Preclinical; Glutamate Carboxypeptida | 2009 |
A low molecular weight PSMA-based fluorescent imaging agent for cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorescent Dyes; Glutamate Carboxypeptidase II; Gluta | 2009 |
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Topics: Amides; Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assa | 2010 |
Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo.
Topics: Animals; Biomarkers, Tumor; Enzymes; Fumarates; Gadolinium; Hydrogen-Ion Concentration; Indicators a | 2010 |
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, An | 2010 |
Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Chromans; Dose-Response R | 2011 |
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Proliferation; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; | 2011 |
Investigating tumor perfusion and metabolism using multiple hyperpolarized (13)C compounds: HP001, pyruvate and urea.
Topics: Animals; Carbon Isotopes; Contrast Media; Cyclopropanes; Disease Models, Animal; Imaging, Three-Dime | 2012 |
68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; Ede | 2012 |
Frequency-specific SSFP for hyperpolarized ¹³C metabolic imaging at 14.1 T.
Topics: Animals; Carbon Isotopes; Computer Simulation; Humans; Magnetic Resonance Imaging; Male; Mice; Model | 2013 |
Synthesis and cytotoxicity of new 3-alkyl-1-(1-methyl-2-phenylethyl)ureas related to ceramide.
Topics: Ceramides; Colonic Neoplasms; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Kidney | 2003 |
UREA-CREATININE RATIO IN OBSTRUCTIVE UROPATHY AND RENAL HYPERTENSION.
Topics: Acute Kidney Injury; Blood; Blood Urea Nitrogen; Creatine; Creatinine; Humans; Hypertension, Renal; | 1964 |
Predicting altered pathways using extendable scaffolds.
Topics: Bayes Theorem; Computational Biology; Gene Expression Profiling; Glutathione; Humans; Male; Models, | 2006 |
[Determinations of catalase in urine and its significance for clinical procedures].
Topics: Adenocarcinoma; Catalase; Cystitis; Glomerulonephritis; Glycerol; Hepatitis; Humans; Hydrogen Peroxi | 1966 |
Prostatic acid phosphatase, purification and iodination using Iodogen.
Topics: Acid Phosphatase; Adenoma; Chromatography; Drug Stability; Humans; Imidazoles; Immunoelectrophoresis | 1982 |
Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections.
Topics: Antigens, Neoplasm; Buffers; Carcinoma; Citrates; Citric Acid; Frozen Sections; Humans; Immunoenzyme | 1993 |
Red blood cell polyamines, anaemia and tumour growth in the rat.
Topics: Anemia; Animals; Erythrocyte Count; Erythrocytes; Erythropoietin; Iron; Male; Neoplasm Transplantati | 1996 |
Changes in urate metabolism after castration of patients suffering from carcinoma of the prostate.
Topics: Creatinine; Humans; Longitudinal Studies; Male; Orchiectomy; Prostatic Neoplasms; Reference Values; | 1991 |
Diagnosis, characterization and management of post-obstructive diuresis.
Topics: Aged; Creatinine; Desoxycorticosterone; Diuresis; Edema; Heart Failure; Humans; Hypertension; Infusi | 1973 |
Carcinoma of the prostate. A retrospective analysis of conventional management in 110 cases.
Topics: Acid Phosphatase; Age Factors; Aged; Blood Sedimentation; Diagnosis, Differential; Estrogens; Hemogl | 1973 |
[Consumption coagulopathy in metastatic prostatic carcinoma].
Topics: Acid Phosphatase; Adenoma; Aged; Alkaline Phosphatase; Bilirubin; Blood Coagulation Disorders; Blood | 1968 |
Platelet adhesiveness and lipoprotein lipase activity in patients with benign and malignant disease of the prostate.
Topics: Aged; Estrogens; Heparin; Humans; Lipoprotein Lipase; Male; Platelet Adhesiveness; Prostatic Disease | 1972 |